CA
NZ
UK
AU
IND
US
MoonLake describes itself as a single-asset company. In June 2026, week 52 data from the VELA-1 and VELA-2 trials showed 67.2% of treated patients (n=396) achieving HiSCR75 and 33.1% achieving HiSCR100. An interim VELA-TEEN analysis at week 24 showed about 68% of 22 adolescent …
Lorundrostat is an orally administered aldosterone synthase inhibitor under development for uncontrolled or resistant hypertension, along with chronic kidney disease and obstructive sleep apnea. The company said it has completed six clinical trials, including the Phase 3 Launch-HTN and Phase 2 Advance-HTN pivotal studies. …
Revenue of USD 80.25 million compares with USD 70.02 million in the third quarter of 2025.Gross Profitwas USD 63.25 million, a grossMarginof 79%, against USD 55.23 million. Sales andMarketingexpenses were USD 23.82 million against USD 21.35 million.
On August 17, the company issued USD 350 million of 4.85% senior notes due 2029 and USD 600 million of 5.65% senior notes due 2036. Net proceeds were about USD 942 million, used to fund part of the D-Fend purchase. The company recognized USD …
Net premiums earned were USD 238.46 million, against USD 241.75 million. The company attributed the decline mainly to higher ceded premiums earned, with net premiumYieldat 31.2 basis points against 32.3. Net investment income was USD 60.9 million, against USD 62.2 million. Annual persistency was …
Management said double-digit organic revenue growth in Storage and Terminal Solutions and in Process and Industrial Facilities, led by specialty storage andMiningand minerals work, offset lowerNatural Gaspeak shaving volumes inUtilityand Power Infrastructure. Book-to-bill was at or above 1.0x in Utility and Power Infrastructure and …
Fourth quarter production is guided to average 174.0 to 182.0 thousand BOE per day, excluding noncontrolling interest. Full year capital expenditures, excluding noncontrolling interest, are guided at USD 1,500 million to USD 1,600 million, funded primarily fromOperating Cash Flowand available cash.
The company entered an agreement to transition its metering business, which operates through its Mueller Systems subsidiary, to ZENNER USA, part of the Minol-ZENNER Group. Metering-related net sales were approximately USD 40 million in fiscal 2026, and fiscal 2027 guidance excludes all metering-related results.
The CEO said the company has accelerated new-generation product development, set a roadmap for differentiated solutions and deepened its Navitas relationship, with an objective of moving beyond competing mainly on price. He added that the transformation takes time and that near-term headwinds remain. During …
President and chief executive Sam Raha said the Prenatal Health sale supports the intent to increase profitable growth by focusing on the Cancer Care Continuum, which covers screening, treatment selection, monitoring and remission surveillance. He also said third quarter results came in ahead of …
Please wait processing your request...